Patrick Myers of Geneva University in Switzerland moderates a discussion on the recently published ORBITA trial
. Dr Meyers is joined by David Taggart of the University of Oxford in the UK and Michael Mack of Baylor Scott and White Health in Dallas, Texas, US. The group discusses the importance of the sham-control design of the trial, ORBITA’s context within previous and upcoming trials, and what the results mean for cardiac surgeons.
Read the paper here:
Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial [published online ahead of print November 1, 2017]. Lancet. doi:10.1016/S0140-6736(17)32714-9